ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
11/20
01:16 pm
arwr
Low
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
11/18
07:45 am
arwr
Low
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran [Yahoo! Finance]
11/18
07:33 am
arwr
Low
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome [Yahoo! Finance]
11/18
07:31 am
arwr
Low
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
11/18
07:30 am
arwr
Low
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
8/8/2024
04:01 pm
ARWR
-9.4%
MISS
5/9/2024
04:01 pm
ARWR
-10.7%
MISS
11/20
01:16 pm
Reiterates
Buy
Buy
HC Wainwright
Low
1.2%
10/11
03:42 pm
Reiterates
Buy
Buy
HC Wainwright
Low
0.5%
9/26
10:15 am
Reiterates
Outperform
Outperform
Royal Bank of Canada
Low
-1.7%
9/26
10:15 am
Reiterates
Outperform
Outperform
Royal Bank of Canada
Low
-1.7%
9/26
10:06 am
Reiterates
Outperform
Outperform
RBC Capital
Low
-2.0%
11/15
08:34 pm
arwr
Low
Form 5 ARROWHEAD PHARMACEUTICAL For: Sep 30 Filed by: Lu Hongbo
11/14
09:38 am
arwr
Low
Form SC 13G ARROWHEAD PHARMACEUTICAL Filed by: Avoro Capital Advisors LLC
10/16
09:15 am
arwr
Medium
Form SC 13G/A ARROWHEAD PHARMACEUTICAL Filed by: STATE STREET CORP
Show more
Top News Gainers
3/18 Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm 23.9%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
Top News Decliners
3/15 Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? [Yahoo! Finance News] -16.8%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3